IFITM1 and endometrioid stromal sarcoma: Interestingly, our study found that both CD10 and IFITM1 were significantly more commonly expressed in LG-ESS cases with a recurrent fusion, which underscores the diagnostic challenges of fusion-negative tumors given the lack of recurrent genetic alterations and potentially more equivocal IHC results.